Japanese encephalitis vaccines - Needs, flaws and achievements

Biological Chemistry

Volumn 389, Issue 5, 2008, Pages 547-550

  Tauber, Erich ^a   Dewasthaly, Shailesh ^a  

^a INTERCELL AG   (Austria)

Author keywords

Flavivirus; IC51; Immunogenicity; Southeast Asia

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIHISTAMINIC AGENT; CHIMERIVAX; GELATIN; IC 51; INACTIVATED VIRUS VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; STEROID; THIOMERSAL;

ALCOHOL CONSUMPTION; ANGIONEUROTIC EDEMA; ASIA; CHILDHOOD; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC ENCEPHALITIS; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFECTION RISK; JAPANESE ENCEPHALITIS VIRUS; JOINT SWELLING; MASS IMMUNIZATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RASH; SHORT SURVEY; SINGLE DRUG DOSE; STEROID THERAPY; TRAVEL; UNSPECIFIED SIDE EFFECT; URTICARIA; VACCINATION REACTION; VERO CELL; WHEEZING;

ANIMALS; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES;

FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS;

EID: 45749141637     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.062     Document Type: Short Survey

References (34)

1. Acambis plc (2007). Acambis' JE vaccine meets and exceeds primary endpoint in pivotal Phase 3 efficacy trial. Press release March 1, 2007. Available at: www.acambis.co.uk/default.asp?ids1839.
2. Anderson, M.M. and Ronne, T. (1991). Side-effects with Japanese encephalitis vaccine. Lancet 337, 1044.
3. Berg, S.W., Mitchell, B.S., Hanson, R.K., Olafson, R.P., Wiliams, R.P., Tueller, J.E., Burton, R.J., Novak, D.M., Tsai, T.F., and Wignall, F.F. (1997). Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin. Infect. Dis. 24, 265-266.
4. Biken (1997). JE-VAX® wpackage insertx (Osaka, Japan: Biken).
5. Centers for Disease Control and Prevention (1993). Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 42, No. RR-1.
6. Centers for Disease Control and Prevention (2008). Travelers' health: Yellow Book. Chapter 4: Prevention of specific infectious diseases: Japanese encephalitis. Available at: http://wwwn.cdc.gov/travel/yellowBookCh4- JapaneseEncephalitis.aspx.
7. DeFraites, R.F. (1992). Immunogenicity and Safety of Japanese encephalitis vaccine (inactivated: Nakayama/BIKEN) in US Army soldiers: evaluation of three consecutively manufactured lots of vaccine administered in two dosing regimen. Unpublished data, on file with BIKEN and with Walter Reed Army Institute of Research, Washington, DC, USA.
8. Halstead, S.B. and Jacobson, J. (2003). Japanese encephalitis. Adv. Virus Res. 61, 103-138.
9. Halstead, S.B. and Tsai, T.F. (2004). Japanese encephalitis vaccine. In: Vaccines, 4th edition, S.A. Plotkin and W.A. Orenstein, eds. (Philadelphia, USA: W.B. Saunders), pp. 919-958.
10. Hoke, C.H., Nisalak, A. Sangawhipa, N., Jatanasen, S., Laorakapongse, T., Innis, B.L., Kotchasenee, S., Gingrich, J.B., Latendresse, J., Fukai, K., et al. (1988). Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319, 608-614.
11. Hombach, J., Kurane, I., Wood, D. (2004). Arguments for live flavivirus vaccines. Lancet 364, 498-499.
12. Marfin, A.A., Eidex, R.S., Kozarsky, P.E., and Cetron, M.S. (2005). Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect. Dis. Clin. N. Am. 19, 151-168.
13. Marks, J.G., Belsito, D.V., DeLeo, V.A:, Fowler, J.R., Fransway, A.F., Maibach, H.I., Mathias, C.G., Pratt, M.D., Rietschel, R.L., Sherertz, E.F., et al. (2003). North American Contact Dermatitis Group patch-test results, 1998 to 2000. Am. J. Contact Dermatitis 14, 59-62.
14. Monath, T.P., Guirakhoo, F., Nichols, R., Yoksan, S., Schrader, R., Murohy, C., Blum, P., Woodwards, S., McCarthy, K., Mathis, D., et al. (2003). Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase II clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213-1230.
15. Monnet, F.P. (2003). Behavioural disturbances following Japanese B encephalitis. Eur. Psychiatry 18, 269-273.
16. Ostlund, M.R., Kan, B., Karlsson, M., and Vene, S. (2004). Japanese encephalitis in a Swedish tourist after traveling to Java and Bali. Scand. J. Infect. Dis. 36, 512-513.
17. Oya, A. and Kurane, I. (2007). Japanese encephalitis for a reference to international travelers. J. Travel Med. 14, 259-268.
18. Plesner, A.M. and Ronne, T. (1997). Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 15, 1239-1243.
19. Poland, J.D., Cropp, B., Craven, R.B., and Monath, T.P. (1990). Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis. 161, 876-882.
20. Robinson, P., Ruff, T., and Kass, R. (1995). Australian case-control study of adverse reactions to Japanese encephalitis vaccine. J. Travel Med. 2, 159-164.
21. Ruff, T.A., Eisen, D., Fuller, A., and Kass, R. (1991). Adverse reactions to Japanese encephalitis vaccine. Lancet 338, 881-882.
22. Sanchez, J.L., Hoke, C.H., McCowan, J., DeFraites, R.F., Takafuji, E.T., Diniega, B.M., and Pang, L.W. (1990). Further experience with Japanese encephalitis vaccine. Lancet 335, 972-973.
23. Seligman, S.J. and Gould, E.A. (2004). Live flavivirus vaccines: reasons for caution. Lancet 363, 2073-2075.
24. Shlim, D.R. and Solomon, T. (2002). Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin. Infect. Dis. 35, 183-188.
25. Sohn, Y.M. (2000). Japanese encephalitis immunization in South Korea: past, present, and future. Emerg. Infect. Dis. 6, 17-24.
26. Solomon, T. (2004a). Vaccines against Japanese encephalitis. In: Travelers' Vaccines, E.C. Jong and J.N. Zuckerman, eds. (Hamilton, ON, Canada: B.C. Decker Inc.), pp. 219-256.
27. Solomon, T. (2004b). Flavivirus encephalitis. N. Engl. J. Med. 351, 370-378.
28. Tauber, E., Kollaritsch, H., Korinek, M., Rendi-Wagner, P., Jilma, B., Firbas, C., Schranz, S., Jong, E., Klinger, A., Dewasthaly, S., et al. (2007). Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a noninferiority, phase III, randomised controlled trial. Lancet 370, 1847-1853.
29. Tosti, A., Melino, M., and Bardazzi, F. (1986). Systemic reactions due to thimerosal. Contact Dermatitis 15, 187-188.
30. Tsai, T.F. and Yu, Y.X. (1999). Japanese encephalitis vaccines. In: Vaccines, 3rd edition (New York, USA: W.B. Saunders), pp. 671-713.
31. US Medical Services (2006). Immunizations and Chemoprophylaxis. Army Regulation 40-562; BUMEDINST 6230.15A; AFJI 48-110; CG COMDTINST M6230.4F. Available at http://www.uscg.mil/hr/g-wk/wkh/pubs/pdf/immunizations.pdf.
32. World Health Organization (2005). Report of the bi-regional meeting on Japanese encephalitis, Bangkok, Thailand, March 30-April 1, 2005. SEA-CD-142 (limited distribution) (New Delhi, India: WHO Regional Office for Southeast Asia).
33. Xin, Y.Y., Ming, Z.G., Peng, G.Y., Jian, A., and Min, L.H. (1988). Safety of a live-attenuated Japanese encephalitis virus vaccine (SA 14-14-2) for children. Am. J. Trop. Med. Hyg. 39, 214-217.
34. Yang, S.E., Pan, M.J., Tseng, H.F., and Liau, M.Y. (2006). The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine - results from 30 years experience in Taiwan. Vaccine 24, 2669-2673.